Carr Financial Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-10,943
Closed -$265K 194
2025
Q2
$265K Sell
10,943
-1,211
-10% -$28.2K 0.08% 156
2025
Q1
$308K Sell
12,154
-5,217
-30% -$137K 0.1% 134
2024
Q4
$461K Sell
17,371
-5,250
-23% -$142K 0.14% 103
2024
Q3
$655K Sell
22,621
-622
-3% -$18.1K 0.19% 88
2024
Q2
$650K Sell
23,243
-342
-1% -$9.42K 0.21% 84
2024
Q1
$654K Buy
23,585
+14,966
+174% +$415K 0.22% 79
2023
Q4
$248K Sell
8,619
-2,393
-22% -$72.3K 0.09% 148
2023
Q3
$344K Buy
11,012
+355
+3% +$12.6K 0.14% 111
2023
Q2
$391K Sell
10,657
-280
-3% -$10.9K 0.16% 108
2023
Q1
$446K Buy
10,937
+1
+0% +$43 0.2% 93
2022
Q4
$560K Buy
+10,936
New +$524K 0.3% 73

Other funds holding PFE

Carr Financial Group's PFE Position: Q3 2025 in Review

Carr Financial Group sold out of Pfizer (PFE) in Q3 2025, closing a stake of 10,943 shares — an estimated $265K sold.

Carr Financial Group first reported a position in PFE in Q4 2022 and held it in 11 quarters. The position peaked at $655K in Q3 2024. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • Carr Financial Group reported no remaining Pfizer position as of Q3 2025 after selling out during the quarter.
  • Carr Financial Group sold 10,943 Pfizer shares in Q3 2025, an estimated $265K.
  • Carr Financial Group first reported a position in Pfizer in Q4 2022 and held it in 11 quarters.
  • Carr Financial Group's Pfizer position peaked at $655K in Q3 2024.
  • 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on Carr Financial Group's 13F filing for Q3 2025, filed 8 Oct 2025.